Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS

Neurology

Volumn 67, Issue 6, 2006, Pages 944-953

  Kappos, L ^a,k   Traboulsee, A ^b   Constantinescu, C ^c   Eralinna J P ^d   Forrestal, F ^e   Jongen, P ^f   Pollard, J ^g   Sandberg Wollheim, M ^h   Sindic, C ⁱ   Stubinski, B ^e   Uitdehaag, B ^j   Li, D ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF TURKU   (Finland)

^e Serono International SA   (Switzerland)

^f Multiple Sclerosis Centre Nijmegen   (Netherlands)

^g UNIVERSITY OF SYDNEY   (Australia)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA1A INTERFERON; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPLICATION SITE REACTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BRAIN RADIOGRAPHY; BRAIN SIZE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EPILEPSY; EXPANDED DISABILITY STATUS SCALE; FLU LIKE SYNDROME; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SYSTEMIC THERAPY; THYROID DISEASE; TREATMENT DURATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANALYSIS OF VARIANCE; BRAIN; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 33749027200     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000237994.95410.ce     Document Type: Article

References (30)

1. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-261.
2. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;13:119-146.
3. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-1636.
4. Kappos L, Stam Moraga M, Alsop J. Long-term tolerability of interferon beta-1a in relapsing-remitting multiple sclerosis: 6-year safety follow-up of the PRISMS study (poster). Presented at the joint meeting of the American and European Committees for Treatment and Research in Multiple Sclerosis, Baltimore, 2002.
5. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504. Erratum in Lancet 1999;353:678.
6. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
8. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002;59:1507-1517.
9. Clanet M, Kappos L, Hartung HP, Hohlfeld R. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 2004;10:139-144.
10. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
11. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-266.
12. Johnson KP, Ford CC, Lisak RP, Wolinsky JS. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005;111:42-47.
13. Francis GS, Rice GPA, Alsop JC. for the PRISMS Study Group. Results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005;11:626-634.
16. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
17. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134.
18. Traboulsee A, Dehmeshki J, Peters KR, et al. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 2003;9:566-573.
19. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a. Neurology 2005;64:236-240.
20. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis. Brain 2000;123(Pt 11):2256-63.
21. Rudick RA, Fisher E, Lee J-C, Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon b-1a. Mult Scler 2000;6:365-372.
22. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5:158-170.
23. Hoogervorst EL, Polman CH, Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler 2002;8:415-419.
24. Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002;59:688-694.
25. Deleted in proof.
26. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler 2003;9:154-159.
27. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004;62:601-606.
28. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004;62:51-59.
29. Kappos L, Polman C, Thompson AJ, et al. Towards a European Network for Multiple Sclerosis Trials (ENMST). Mult Scler 2003;9:627-629.
30. http://www.slcmsr.net/en/partner/about.html. Accessed March 23, 2006.